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Use of sodium-glucose co-transporter 2 inhibitors and risk of 
serious renal events: Scandinavian cohort study
Björn Pasternak,1,2 Viktor Wintzell,1 Mads Melbye,2,3,4 Björn Eliasson,5 Ann-Marie Svensson,5,6 
Stefan Franzén,6,7 Soffia Gudbjörnsdottir,5,6 Kristian Hveem,8,9 Christian Jonasson,8,9,10 
 Henrik Svanström,1,2 Peter Ueda1
ABSTRACT
OBJECTIVE
To assess the association between use of sodium-
glucose co-transporter 2 (SGLT2) inhibitors and risk 
of serious renal events in data from routine clinical 
practice.
DESIGN
Cohort study using an active comparator, new user 
design and nationwide register data.
SETTING
Sweden, Denmark, and Norway, 2013-18.
PARTICIPANTS
Cohort of 29 887 new users of SGLT2 inhibitors 
(follow-up time: dapagliflozin 66.1%; empagliflozin 
32.6%; canagliflozin 1.3%) and 29 887 new users 
of an active comparator, dipeptidyl peptidase-4 
inhibitors, matched 1:1 on the basis of a propensity 
score with 57 variables. Mean follow-up time was 1.7 
(SD 1.0) years.
EXPOSURES
SGLT2 inhibitors versus dipeptidyl peptidase-4 
inhibitors, defined by filled prescriptions and 
analysed according to intention to treat.
MAIN OUTCOME MEASURES
The main outcome was serious renal events, a 
composite including renal replacement therapy, death 
from renal causes, and hospital admission for renal 
events. Secondary outcomes were the individual 
components of the main outcome.
RESULTS
The mean age of the study population was 61.3 
(SD 10.5) years; 11 108 (19%) had cardiovascular 
disease, and 1974 (3%) had chronic kidney disease. 
Use of SGLT2 inhibitors, compared with dipeptidyl 
peptidase-4 inhibitors, was associated with a reduced 
risk of serious renal events (2.6 events per 1000 
person years versus 6.2 events per 1000 person 
years; hazard ratio 0.42 (95% confidence interval 
0.34 to 0.53); absolute difference −3.6 (–4.4 to −2.8) 
events per 1000 person years). In secondary outcome 
analyses, the hazard ratio for use of SGLT2 inhibitors 
versus dipeptidyl peptidase-4 inhibitors was 0.32 (0.22 
to 0.47) for renal replacement therapy, 0.41 (0.32 to 
0.52) for hospital admission for renal events, and 0.77 
(0.26 to 2.23) for death from renal causes. In sensitivity 
analyses in each of the Swedish and Danish parts of 
the cohort, the model was further adjusted for glycated 
haemoglobin and estimated glomerular filtration rate 
(Sweden and Denmark) and for blood pressure, body 
mass index, and smoking (Sweden only); in these 
analyses, the hazard ratio moved from 0.41 (0.26 to 
0.66) to 0.50 (0.31 to 0.81) in Sweden and from 0.42 
(0.32 to 0.56) to 0.55 (0.41 to 0.74) in Denmark.
CONCLUSIONS
In this analysis using nationwide data from three 
countries, use of SGLT2 inhibitors, compared with 
dipeptidyl peptidase-4 inhibitors, was associated with 
a significantly reduced risk of serious renal events.
Introduction
Type 2 diabetes is the leading cause of kidney failure.1 
Although treatment with angiotensin converting 
enzyme inhibitors and angiotensin receptor blockers 
reduces the risk of adverse renal outcomes in patients 
with diabetes,2-4 the risk remains high and a large need 
exists for new treatments that lower the risk of kidney 
failure. Sodium-glucose co-transporter 2 (SGLT2) 
inhibitors are a class of glucose lowering drugs that also 
reduce blood pressure, body weight, and albuminuria. 
Large clinical trials have shown that these drugs have 
beneficial effects on renal outcomes. In the CREDENCE 
trial, patients with type 2 diabetes and albuminuric 
chronic kidney disease who received canagliflozin 
experienced lower rates of the composite renal outcome 
versus placebo, including end stage kidney disease, a 
doubling of serum creatinine concentration, and death 
from renal causes (hazard ratio 0.66, 95% confidence 
interval 0.53 to 0.81).5 Similarly, rates of composite 
renal outcomes were reduced among patients with 
type 2 diabetes and high cardiovascular risk receiving 
canagliflozin in the CANVAS programme (hazard ratio 
0.58, 0.50 to 0.67),6 empagliflozin in the EMPAREG 
OUTCOME trial (0.61, 0.53 to 0.70),7 and dapagliflozin 
in the DECLARE TIMI-58 trial (0.53, 0.43 to 0.66).8
The data from clinical trials provide evidence for 
the renoprotective effects of SGLT2 inhibitors, but 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Clinical trials have shown that sodium-glucose co-transporter 2 (SGLT2) 
inhibitors protect renal function among patients with type 2 diabetes and high 
cardiovascular risk or established nephropathy
The effect of SGLT2 inhibitors on serious renal events in broader unselected 
groups of patients in routine clinical practice remains uncertain
WHAT THIS STUDY ADDS
This cohort study used nationwide register data from Sweden, Denmark, and 
Norway to compare use of SGLT2 inhibitors and dipeptidyl peptidase-4 inhibitors
Use of SGLT2 inhibitors was associated with a 58% lower risk of a composite 
outcome of serious renal events, including renal replacement therapy, death 
from renal causes, and hospital admission for renal events
Complementing the results of randomised trials, these data suggest that SGLT2 
inhibitors may lower the risk of serious renal events in routine clinical practice
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uncertainty remains about the effect of these drugs 
on renal outcomes in routine clinical practice. The 
four large clinical trials assessing renal outcomes with 
SGLT2 inhibitors have included only patients at high 
cardiovascular risk or with established nephropathy.5-8 
Patients receiving SGLT2 inhibitors in clinical practice 
tend to be more heterogenous,9 and whether the 
findings of the clinical trials are generalisable to broad, 
unselected groups of patients is unknown.
Using nationwide data from patients seen in routine 
clinical practice in Sweden, Denmark, and Norway, 
we did a register based cohort study to assess whether 
use of SGLT2 inhibitors, compared with an active 
comparator (dipeptidyl peptidase-4 inhibitors), is 
associated with a reduced risk of serious renal events.
Methods
Data sources
We used data from nationwide health and administrative 
registers in Sweden (April 2013 through December 
2016), Denmark (April 2013 through December 
2018), and Norway (April 2013 through December 
2016). Data sources included population registers 
and Statistics Denmark/Statistics Sweden (vital status, 
demographics, socioeconomic variables), patient 
registers (comorbidities, outcomes), prescription 
registers (study drugs, co-medications), cause of death 
registers (outcomes; data from this register in Denmark 
were available through 2017), the Swedish National 
Diabetes Register (glycated haemoglobin level, 
blood pressure, albuminuria, estimated glomerular 
filtration rate, body mass index, and smoking), and 
the Danish Register of Laboratory Results for Research 
(glycated haemoglobin, albuminuria, and estimated 
glomerular filtration rate); details are provided in the 
supplementary material.
Active comparator, new user design
We used an active comparator, new user design to 
mitigate the risk of confounding by indication, disease 
severity, and unmeasured clinical characteristics.10 
The ideal active comparator would be a drug that is 
used in similar clinical situations to SGLT2 inhibitors 
and has no expected associations with the investigated 
outcomes. We used dipeptidyl peptidase-4 inhibitors 
as the active comparator, as clinical guidelines used 
during the study period recommended both SGLT2 
inhibitors and dipeptidyl peptidase-4 inhibitors 
as second line or third line glucose lowering 
therapies and data from clinical trials in patients 
at high cardiovascular risk indicate that dipeptidyl 
peptidase-4 inhibitors have no or limited effects on 
renal outcomes.11 12
Study population
We included all patients aged 35-84 years in the 
three countries who filled their first prescription for 
either an SGLT2 inhibitor or a dipeptidyl peptidase-4 
inhibitor during the study period (anatomic 
therapeutic chemical codes for study drugs are shown 
in supplementary table A). The date of filling the first 
prescription constituted cohort entry. Exclusion criteria 
were previously filled prescriptions for any of the study 
drugs within two years of cohort entry, no specialist 
care contact or prescription drug in the previous year, 
history of dialysis or renal transplantation, end stage 
illness, drug misuse, severe pancreatic disorders, and 
hospital admission for any reason within 30 days 
before cohort entry (supplementary table B).
Using logistic regression, we estimated the 
probability of starting a SGLT2 inhibitor versus 
a dipeptidyl peptidase-4 inhibitor, conditional 
on the status of 57 covariates at cohort entry; the 
score included variables on sociodemographic 
characteristics, comorbidities, co-medications, and 
healthcare utilisation (supplementary table C). We 
used missing categories to handle missing data on 
place of birth (<1%), civil status (<1%), and education 
(<3%)13; none of the other variables had missing 
data. We estimated propensity scores in each country 
separately. Owing to variations in data availability, 
a few variables included in the propensity score in 
Norway differed slightly from those in Sweden and 
Denmark (supplementary table C).
We matched new users of SGLT2 inhibitors and 
dipeptidyl peptidase-4 inhibitors (1:1 ratio) by using 
the nearest neighbour algorithm (calliper width 0.2 of 
the standard deviation of the logit propensity score),14 15 
with sex, age (5 year intervals), and a previous diagnosis 
of chronic kidney disease (supplementary table D) as 
additional matching criteria. We considered covariates 
to be well balanced if the standardised difference was 
below 10%. We did the analyses in a pooled dataset of 
the matched cohorts of the three countries.
Outcomes
The primary outcome, serious renal events, was a 
composite of renal replacement therapy (dialysis or 
renal transplantation), death from renal causes, and 
hospital admission for renal events, as captured in 
the patient registers and the cause of death registers. 
Secondary outcomes were each component of the 
primary outcome.
Hospital admission for renal events was based on 
events consistent with serious renal disease, including 
diabetic nephropathy, chronic kidney disease, and 
acute kidney injury; we considered this outcome as a 
renal analogue to the outcome of hospital admission 
for heart failure in cardiology, in that we regarded it 
as an indicator of serious worsening of renal status. 
Supplementary table E shows ICD-10 (international 
classification of diseases, version 10) codes and 
procedure codes used to define the outcomes. In 
validation studies of diagnostic codes for renal events 
used in health registers, sensitivity has varied widely, 
whereas specificity was high.16 Validation studies have 
not been done in the Scandinavian setting and for the 
specific codes used in our analyses.
Statistical analyses
We followed patients from cohort entry until outcome 
event, death, emigration, three years of follow-up, or 
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the end of the study period. Patients were censored at 
the time of the first outcome event in the analyses of the 
primary outcome; in analyses of secondary outcomes, 
patients were censored at the first occurrence of the 
outcome analysed, independent of other outcomes. 
We used an intention to treat exposure definition in 
which patients were defined as being exposed to the 
study drug from cohort entry throughout follow-up. We 
used Cox proportional hazards regression with time 
since cohort entry as the time scale to estimate hazard 
ratios. We examined the assumption of proportional 
hazards by using a Wald test of the interaction between 
treatment status and time. We considered hazard ratios 
with 95% confidence intervals that did not overlap 1 to 
be statistically significant. We estimated the absolute 
rate difference assuming a Poisson distribution.
For the primary outcome, we did subgroup analyses 
by sex, age group, history of major cardiovascular 
disease (supplementary table F), and history of 
chronic kidney disease. We used an interaction term 
between treatment status and subgroup to assess effect 
modification by subgroup status; in these analyses, 
we considered a P value below 0.05 to be statistically 
significant. We also analysed the primary outcome by 
country to assess consistency across data sources and 
in separate analyses for patients starting empagliflozin 
and dapagliflozin (and their 1:1 matched users of 
dipeptidyl peptidase-4 inhibitors), respectively; this 
analysis was not possible for canagliflozin, as few 
patients used this drug.
In an additional analysis, we used an as-treated 
exposure definition based on the estimated duration 
of the filled prescriptions (supplementary table A), 
allowing for a 30 day grace period to account for 
prescription overlap, irregular drug use, and events 
that occurred shortly after treatment cessation. In 
these analyses, patients were censored at treatment 
cessation and crossover to the other study drug (that is, 
start of dipeptidyl peptidase-4 inhibitors among users 
of SGLT2 inhibitors and vice versa).
We did several sensitivity analyses. Firstly, we 
adjusted the analysis of the primary outcome for 
calendar year of cohort entry. Next, in analyses in 
each of the propensity score matched cohorts in 
Sweden and Denmark, we adjusted the Cox models 
for additional variables. In Sweden, these variables 
included glycated haemoglobin level, blood pressure, 
albuminuria, estimated glomerular filtration rate, body 
mass index, and smoking; in Denmark, they included 
glycated haemoglobin level, albuminuria, and 
estimated glomerular filtration rate (supplementary 
table G). Owing to the proportion of patients with 
missing data for these variables (supplementary table 
G), we used multiple imputation (fully conditional 
specification imputation) to handle missing data 
and used 10 imputed datasets for the analyses.17 On 
the basis of the imputed datasets, we also did the 
analyses in subgroups of patients by level of estimated 
glomerular filtration rate (<60 v ≥60 per 1.73 m2 body 
surface area) and the presence of albuminuria. For 
these analyses, we estimated hazard ratios separately 
for each subgroup in each country and combined them 
using meta-analysis assuming fixed effects.
Patient and public involvement
No patients were involved in setting the research 
question, nor in the design, conduct, or interpretation 
of the study. The study is based on anonymised 
nationwide register data, and no dissemination of 
results directly to study participants is planned.
Results
Study population
In all, 38 273 new users of SGLT2 inhibitors and 
107 854 new users of dipeptidyl peptidase-4 inhibitors 
fulfilled study eligibility criteria (fig 1). Supplementary 
table H shows the baseline characteristics of the cohort 
before matching, and supplementary tables I-K show 
the characteristics of the patients by country. After 
one-to-one matching, the cohort included 29 887 
new users of SGLT2 inhibitors and 29 887 new users 
of dipeptidyl peptidase-4 inhibitors. Covariates in the 
two groups were well balanced (table 1). The mean age 
was 61.3 (SD 10.5) years, 39.3% were female, 18.6% 
had a history of major cardiovascular disease, and 
3.3% had a history of chronic kidney disease. Total 
follow-up time in the primary analysis was 42 632 
years (mean 1.4 (1.0) years) among SGLT2 inhibitor 
users and 58 473 years (mean 2.0 (1.0) years) among 
dipeptidyl peptidase-4 inhibitor users. Mean follow-
up time overall was was 1.7 (SD 1.0) years Of the 
total follow-up for SGLT2 inhibitors, the proportion 
of follow-up time by drug started at cohort entry was 
66.1% for dapagliflozin, 32.6% for empagliflozin, and 
1.3% for canagliflozin. For dipeptidyl peptidase-4 
inhibitors, the proportions were 64.8% for sitagliptin, 
20.0% for vildagliptin, 10.2% for linagliptin, 2.8% for 
saxagliptin, and 2.2% for alogliptin (supplementary 
table L).
Primary and secondary outcomes
Figure 2 shows the cumulative incidence of the primary 
composite outcome, serious renal events. Use of SGLT2 
inhibitors, compared with dipeptidyl peptidase-4 
inhibitors, was associated with a significantly lower 
risk of serious renal events (incidence rate 2.6 events 
per 1000 person years versus 6.2 events per 1000 
person years; hazard ratio 0.42, 95% confidence 
interval 0.34 to 0.53) (table 2). When we assessed 
the proportional hazards assumption, we observed a 
significant interaction between year of follow-up and 
exposure to SGLT2 inhibitors (P=0.009; Schoenfeld 
residuals are shown in supplementary figure A). The 
association of SGLT2 inhibitors with lower risk of 
serious renal events was largely driven by the first two 
years of follow-up (hazard ratio 0.34 (0.25 to 0.47) for 
year 1 after cohort entry, 0.43 (0.30 to 0.64) for year 2, 
and 0.74 (0.46 to 1.17) for year 3).
In the analyses of the secondary outcomes, use 
of SGLT2 inhibitors, compared with dipeptidyl 
peptidase-4 inhibitors, was associated with a 
significantly lower risk of renal replacement therapy 
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(incidence rate 0.8 v 2.5 per 1000 person years; hazard 
ratio 0.32, 0.22 to 0.47) and hospital admission for 
renal events (2.0 v 4.9 per 1000 person years; 0.41, 
0.32 to 0.52) but not death from renal causes (0.2 v 0.2 
per 1000 person years; 0.77, 0.26 to 2.23) (table 2).
Subgroup and additional analyses
Figure 3 shows subgroup analyses. We observed 
no significant interaction between use of SGLT2 
inhibitors and the primary outcome in analyses by 
sex and age group. Hazard ratios were lower for 
patients with a history of cardiovascular disease 
than for those without (0.30 (0.21 to 0.44) versus 
0.52 (0.40 to 0.67); P for interaction=0.022) and for 
those with a history of chronic kidney disease versus 
those without (0.18 (0.10 to 0.31) versus 0.52 (0.41 
to 0.65); P for interaction<0.001). Hazard ratios were 
consistent across countries (supplementary table M; 
supplementary figure B). The hazard ratio was 0.33 
(0.22 to 0.49) for patients starting empagliflozin and 
0.47 (0.36 to 0.61) for those starting dapagliflozin 
(supplementary table N).
In the additional analyses using an as-treated 
exposure definition, the total follow-up time was 
21 557 years (mean 0.7 (SD 0.6) years) for users of 
SGLT2 inhibitors and 27 314 years (mean 0.9 (0.8) 
years) for users of dipeptidyl peptidase-4 inhibitors. 
In this analysis, the hazard ratio for the association 
between use of SGLT2 inhibitors and the primary 
outcome was 0.30 (0.22 to 0.42) (supplementary 
figure C; supplementary table O) The assumption of 
proportional hazards was met (P=0.69) (supplementary 
figure D).
Sensitivity analyses
In the analysis adjusted for calendar year of cohort 
entry, the hazard ratio was unchanged from the 
primary analyses (0.42, 0.34 to 0.52). The distribution 
of glycated haemoglobin, blood pressure, albuminuria, 
estimated glomerular filtration rate, body mass index, 
and smoking in the Swedish part of the cohort is 
shown in supplementary table P, and the distribution 
of glycated haemoglobin, albuminuria, and estimated 
glomerular filtration rate in the Danish part of the 
cohort is shown in supplementary table Q. Additional 
adjustment for these variables resulted in slightly 
attenuated associations of SGLT2 inhibitors with 
the primary outcome, compared with the analyses 
without such adjustment (Sweden: hazard ratio 0.50 
(0.31 to 0.81) and 0.41 (0.26 to 0.66), respectively; 
Denmark: 0.55 (0.41 to 0.74) and 0.42 (0.32 to 0.56), 
respectively) In the subgroup analyses using the 
imputed datasets, the hazard ratios for patients with 
estimated glomerular filtration rate below 60 and at 
least 60 per 1.73 m2 body surface area were 0.47 (0.30 
to 0.72) and 0.60 (0.44 to 0.82), respectively. The 
hazard ratios for those with and without albuminuria 
were 0.45 (0.29 to 0.69) and 0.62 (0.43 to 0.90), 
respectively (supplementary table R).
Discussion
In this cohort study using nationwide registers in three 
countries, use of SGLT2 inhibitors was associated with 
a lower risk of the main composite outcome of serious 
renal events (consisting of renal replacement therapy, 
renal death, and hospital admission for renal events) 
in analyses using dipeptidyl peptidase-4 inhibitors 
Propensity score estimation and 1:1 matching
Patients included in matched cohort
29 887   New users of SGLT2 inhibitors 29 887   New users of DPP4 inhibitors
Excluded*
Previous use of SGLT2 inhibitors
No specialist care contact and no use
  of prescription drugs in previous year
Dialysis or renal transplantation
End stage illness
Drug misuse
Severe pancreatic disorder
Hospital admission in previous 30 days
34
905
1424
1831
1088
1010
9850
Excluded*
Previous use of DPP4 inhibitors
No specialist care contact and no
  use of prescription drugs in
  previous year
Dialysis or renal transplantation
End stage illness
Drug misuse
Severe pancreatic disorder
Hospital admission in previous
  30 days
13 163
149
135
325
415
510
1842
New users of SGLT2 inhibitors New users of DPP4 inhibitors
54 110
14 77015 837
122 624
New users of SGLT2 inhibitors eligible for inclusion New users of DPP4 inhibitors eligible for inclusion
38 273
59 774
107 854
Fig 1 | Flowchart of patient inclusion in study cohort, Sweden, Denmark, and Norway. DPP4=dipeptidyl peptidase-4; 
SGLT2=sodium-glucose co-transporter 2. *Patients could be excluded for more than one reason
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Characteristics
SGLT2 inhibitors 
(n=29 887)
DPP4 inhibitors 
(n=29 887)
Standardised mean 
difference (%)
Country*:
 Sweden 9241 (30.9) 9241 (30.9) -
 Denmark 14 232 (47.6) 14 232 (47.6) -
 Norway 6414 (21.5) 6414 (21.5) -
Male sex 18 129 (60.7) 18 129 (60.7) -
Mean (SD) age, years 61.3 (10.5) 61.3 (10.5) 0.4
Age group, years:
 35-39 744 (2.5) 744 (2.5) -
 40-44 1447 (4.8) 1447 (4.8) -
 45-49 2534 (8.5) 2534 (8.5) -
 50-54 3787 (12.7) 3787 (12.7) -
 55-59 4551 (15.2) 4551 (15.2) -
 60-64 4921 (16.5) 4921 (16.5) -
 65-69 5166 (17.3) 5166 (17.3) -
 70-74 4006 (13.4) 4006 (13.4) -
 75-79 1948 (6.5) 1948 (6.5) -
 80-84 783 (2.6) 783 (2.6) -
Place of birth:
 Scandinavia 25 000 (83.6) 25 082 (83.9) 0.7
 Rest of Europe 1977 (6.6) 1951 (6.5) 0.4
 Outside Europe 2866 (9.6) 2812 (9.4) 0.6
 Missing 44 (0.1) 42 (0.1) 0.2
Civil status:
 Married/living with partner 17 533 (58.7) 17 608 (58.9) 0.5
 Single 12 248 (41.0) 12 178 (40.7) 0.5
 Missing 106 (0.4) 101 (0.3) 0.3
Education†:
 Primary/secondary school, vocational training 18 455 (78.6) 18 556 (79.1) 1.1
 Short tertiary education 1384 (5.9) 1414 (6.0) 0.5
 Medium or long tertiary education 2975 (12.7) 2887 (12.3) 1.1
 Missing 659 (2.8) 616 (2.6) 1.1
Medical history:
 Acute coronary syndrome 2145 (7.2) 2039 (6.8) 1.4
 Other ischaemic heart disease 4978 (16.7) 4729 (15.8) 2.3
 Heart failure/cardiomyopathy 1682 (5.6) 1560 (5.2) 1.8
 Valve disorders 727 (2.4) 666 (2.2) 1.4
 Stroke 1166 (3.9) 1160 (3.9) 0.1
 Other cerebrovascular disease 1268 (4.2) 1230 (4.1) 0.6
 Atrial fibrillation 2066 (6.9) 1939 (6.5) 1.7
 Other arrhythmia 1258 (4.2) 1137 (3.8) 2.1
 Coronary revascularisation in previous year 438 (1.5) 436 (1.5) 0.1
  Other cardiac surgery/invasive procedure in previous year 152 (0.5) 126 (0.4) 1.3
 Arterial disease 1872 (6.3) 1871 (6.3) <0.1
 Chronic kidney disease 987 (3.3) 987 (3.3) -
 Other renal disease 1664 (5.6) 1559 (5.2) 1.6
 Diabetic complications 8069 (27.0) 7828 (26.2) 1.8
 Chronic obstructive pulmonary disease 1184 (4.0) 1127 (3.8) 1.0
 Other lung disease 2080 (7.0) 2010 (6.7) 0.9
 Venous thromboembolism 693 (2.3) 666 (2.2) 0.6
 Cancer 1981 (6.6) 2002 (6.7) 0.3
 Liver disease 621 (2.1) 622 (2.1) <0.1
 Rheumatic disease 860 (2.9) 845 (2.8) 0.3
 Psychiatric disorder 2594 (8.7) 2572 (8.6) 0.3
 Fracture in previous year 497 (1.7) 492 (1.6) 0.1
Hospital admissions in previous year:
 Cardiovascular causes 1290 (4.3) 1322 (4.4) 0.5
 Type 2 diabetes related causes 259 (0.9) 266 (0.9) 0.3
 Non-cardiovascular/type 2 diabetes related causes 3890 (13.0) 3771 (12.6) 1.2
Outpatient contacts in previous year:
 Cardiovascular causes 2844 (9.5) 2753 (9.2) 1.0
 Type 2 diabetes related causes 5908 (19.8) 5714 (19.1) 1.6
 Non-cardiovascular/type 2 diabetes related causes 16 894 (56.5) 16 713 (55.9) 1.2
Table 1 | Baseline characteristics of propensity score matched cohort of sodium-glucose co-transporter 2 (SGLT2) 
inhibitor users and dipeptidyl peptidase-4 (DPP4) inhibitor users, Sweden, Denmark, and Norway. Values are in 
numbers (percentages) unless stated otherwise
(Continued)
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as an active comparator. Use of SGLT2 inhibitors was 
associated with a significantly lower risk of incident 
renal replacement therapy, as well as hospital 
admission for renal events, but not with death due to 
renal causes.
Interpretation and comparison with previous 
studies
Large clinical trials have shown that SGLT2 
inhibitors can reduce the risk of advanced renal 
outcomes, including renal replacement therapy, 
and protect kidney function in patients at high 
risk of cardiovascular disease or established 
nephropathy.5-8  18 Our study adds to the knowledge 
about SGLT2 inhibitors and renal outcomes by using 
nationwide registers from three countries (Denmark 
(47.6% of the patients), Sweden (30.9%), and Norway 
(21.5%)) to include a large number of patients seen in 
routine clinical practice. Importantly, of the patients 
included in our study, 81% and 97% had no diagnosis 
of cardiovascular disease and chronic kidney disease, 
respectively. Although the absolute risk reduction 
associated with SGLT2 inhibitors was larger in patients 
with cardiovascular disease or chronic kidney disease, 
the protective association of SGLT2 inhibitors was 
also observed in patients without such history. The 
findings from this observational study complement 
the data from clinical trials,5-8 as well as our previous 
observational study of cardiovascular outcomes,19 and 
provide further support for the use of SGLT2 inhibitors 
across a broad range of patients with type 2 diabetes 
with various levels of renal function. SGLT2 inhibitors 
have been suggested to protect the kidney through 
several mechanisms, including favourable effects 
on renal haemodynamics and reduction of tissue 
inflammation and fibrosis.12 20
Although the primary outcome definition used in 
our study did not directly correspond to the composite 
renal outcomes used in clinical trials (which were 
largely driven by albuminuria and changes in estimated 
glomerular filtration rate), the secondary outcome of 
renal replacement therapy can be compared across 
Characteristics
SGLT2 inhibitors 
(n=29 887)
DPP4 inhibitors 
(n=29 887)
Standardised mean 
difference (%)
Diabetes drugs in previous 6 months:
 None 2316 (7.7) 2201 (7.4) 1.5
 Metformin 24 339 (81.4) 24 541 (82.1) 1.8
 Sulfonylureas 5724 (19.2) 5741 (19.2) 0.1
 Glucagon-like peptide 1 receptor agonists 2607 (8.7) 2549 (8.5) 0.7
 Insulin 7852 (26.3) 7924 (26.5) 0.5
Other antidiabetics (glitazones, glinides, acarbose) 715 (2.4) 717 (2.4) <0.1
Time since first diabetes drug, years:
 <1 3969 (13.3) 4029 (13.5) 0.6
 1-3 3812 (12.8) 3865 (12.9) 0.5
 >3-5 3598 (12.0) 3591 (12.0) 0.1
 >5-7 3862 (12.9) 3920 (13.1) 0.6
 >7 14 646 (49.0) 14 482 (48.5) 1.1
Prescription drugs in previous year:
 ACEi/ARB 19 589 (65.5) 19 396 (64.9) 1.4
 Calcium channel blocker 8953 (30.0) 8759 (29.3) 1.4
 Loop diuretic† 3206 (13.7) 3024 (12.9) 2.3
 Other diuretic† 4347 (18.5) 4205 (17.9) 1.6
 β blocker 9871 (33.0) 9648 (32.3) 1.6
 Digoxin 639 (2.1) 639 (2.1) <0.1
 Nitrate 1964 (6.6) 1900 (6.4) 0.9
 Platelet inhibitor 10 516 (35.2) 10 406 (34.8) 0.8
 Anticoagulant 2198 (7.4) 2057 (6.9) 1.8
 Lipid lowering drug 20 467 (68.5) 20 380 (68.2) 0.6
 Antidepressant 4539 (15.2) 4527 (15.1) 0.1
 Antipsychotic 1164 (3.9) 1165 (3.9) <0.1
 Anxiolytic hypnotic or sedative 4654 (15.6) 4572 (15.3) 0.8
 β-2 agonist inhalant 2854 (9.5) 2772 (9.3) 0.9
 Anticholinergic inhalant 903 (3.0) 879 (2.9) 0.5
 Glucocorticoid inhalant 2822 (9.4) 2717 (9.1) 1.2
 Oral glucocorticoid 2081 (7.0) 2069 (6.9) 0.2
 Non-steroidal anti-inflammatory drug 7478 (25.0) 7475 (25.0) <0.1
 Opioid 5634 (18.9) 5560 (18.6) 0.6
No of prescription drugs in previous year†:
 0-5 5481 (23.4) 5643 (24.0) 1.6
 6-10 9681 (41.2) 9647 (41.1) 0.3
 11-15 5382 (22.9) 5332 (22.7) 0.5
 >15 2929 (12.5) 2851 (12.1) 1.0
ACEi=angiotensin converting enzyme inhibitor; ARB,=angiotensin receptor blocker.
*Propensity score matching was done separately by country.
†Not available in Norwegian dataset; numbers are shown for patients in Sweden and Denmark.
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studies. For this outcome, we observed a hazard ratio 
of 0.32 (95% confidence interval 0.22 to 0.47) for use 
of SGLT2 inhibitors versus dipeptidyl peptidase-4 
inhibitors, which is broadly in line with the hazard 
ratio versus placebo for renal replacement therapy in 
the EMPAREG OUTCOME trial of empagliflozin (0.45, 
0.21 to 0.97)7 and for end stage kidney disease in the 
DECLARE-TIMI 58 trial of dapagliflozin (0.31, 0.13 to 
0.79),8 whereas the hazard ratio for end stage kidney 
disease in the CREDENCE trial of canagliflozin was 
slightly higher (0.68, 0.54 to 0.86).5 Dapagliflozin 
(66.1% of the total follow-up time among users of SGLT2 
inhibitors) and empagliflozin (32.6%) were the most 
common SGLT2 inhibitors in our study population, but 
use of canagliflozin was rare (1.3%). With respect to 
event rates, the incidence of renal replacement therapy 
was substantially higher in the CREDENCE trial (13.3 
(canagliflozin) versus 17.7 (placebo) per 1000 person 
years) than in our study (0.8 (SGLT2 inhibitors) versus 
2.5 (dipeptidyl peptidase-4 inhibitors) per 1000 person 
years), in which event rates were similar to those of the 
EMPAREG OUTCOME trial (1.0 (emplagliflozin) versus 
2.1 (placebo) per 1000 person years). Whereas the 
CREDENCE trials included patients with an estimated 
glomerular filtration rate of 30 to less than 90 mL/min 
per 1.73 m2 and albuminuria, SGLT2 inhibitors were 
used in a broad range of patients in routine clinical 
practice, although these drugs were not recommended 
in patients with an estimated glomerular filtration rate 
of less than 45 mL/min per 1.73 m2 during the study 
period.
We attempted to limit the risk of confounding by 
using a propensity score including a wide range of 
patient characteristics. Moreover, we used a new user 
design excluding patients with a history of using any 
of the study drugs at cohort entry; this design removed 
the possibility of immortal time bias, which has been 
highlighted in other observational analyses of SGLT2 
inhibitors.21 Another strength of the study was the use 
of data on glycated haemoglobin level, albuminuria, 
and estimated glomerular filtration rate (Sweden and 
Denmark), as well as blood pressure, body mass index, 
and smoking (Sweden) in the Swedish and Danish 
parts of the cohort (78.5% of the overall cohort). When 
the outcome models were further adjusted for these 
variables in sensitivity analyses, the point estimate 
for the primary outcome moved from 0.41 to 0.50 in 
Sweden and from 0.42 to 0.55 in Denmark, indicating 
that the primary analyses may present slightly 
overestimated associations owing to confounding by 
these variables.
We used DPP4 inhibitors as the active comparator 
drug class to mitigate the risk of confounding by 
indication, disease severity, and unmeasured clinical 
characteristics. During the study period, both 
dipeptidyl peptidase-4 inhibitors and SGLT2 inhibitors 
were recommended as second or third line glucose 
lowering drugs, and the two drug classes were thus 
used in similar clinical situations and at a similar 
stage of disease.11 In accordance with their neutral 
effect on cardiovascular outcomes and mortality, data 
from clinical trials in patients at high cardiovascular 
risk indicate that dipeptidyl peptidase-4 inhibitors 
have no or limited effects on renal outcomes.12 The 
risk of composite renal outcomes was similar among 
patients receiving active treatment and placebo 
in the SAVOR TIMI 53 trial of saxagliptin and the 
CARMELINA trial of linagliptin,22 23 although some 
potential benefit was indicated in exploratory analyses 
of albuminuria outcomes.23 24 In the EXAMINE 
trial, the risks of dialysis and changes in estimated 
glomerular filtration rate were similar in patients 
receiving alogliptin and placebo.25 In the TECOS trial 
of sitagliptin, which comprised 64.8% of the DPP4 
inhibitor use in our study, the decline in estimated 
Years since start of treatment
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Fig 2 | Cumulative incidence of serious renal events in users of sodium-glucose co-
transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors
Table 2 | Association between use of sodium-glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors for primary 
and secondary outcomes of serious renal events
Outcome
SGLT2 inhibitors (n=29 887) DPP4 inhibitors (n=29 887)
Hazard ratio (95% CI)
Absolute difference, events 
(95% CI) per 1000 person yearsEvents
Events per 1000 
person years Events
Events per 1000 
person years
Primary outcome* 111 2.6 360 6.2 0.42 (0.34 to 0.53) −3.6 (−4.4 to −2.8)
Secondary outcomes:
  Renal replacement therapy 33 0.8 146 2.5 0.32 (0.22 to 0.47) −1.7 (−2.2 to −1.2)
  Death from renal causes† 5 0.2 11 0.2 0.77 (0.26 to 2.23) −0.1 (−0.2 to 0.1)
  Hospital admission for renal events 85 2.0 285 4.9 0.41 (0.32 to 0.52) −2.9 (−3.6 to −2.2)
*Serious renal events, a composite of renal replacement therapy, death from renal causes, and hospital admission for renal events.
†Analysis of death from renal causes included 24 639 new users of SGLT2 inhibitors and 27 857 new users of DPP4 inhibitors, as data on cause of death were available only until 2017 in 
Denmark and patients starting a study drug after this year were not included.
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glomerular filtration rate was clinically similar in 
patients receiving active treatment and placebo.26 If 
dipeptidyl peptidase-4 inhibitors have a protective 
effect on renal outcomes, the associations observed 
in our study may represent an underestimation of 
the effects of SGLT2 inhibitors. However, this would 
not change the overall interpretation of our analyses, 
and the study would still present a head-to-head 
comparative effectiveness analysis of SGLT2 inhibitors 
and dipeptidyl peptidase-4 inhibitors. Furthermore, 
comparative effectiveness analyses of other drug 
classes with demonstrated renoprotective effects,12 
such as glucagon-like peptide-1-receptor-agonists, 
remain a topic for future investigation.
Limitations of study
Our study has limitations. Firstly, the definition of 
exposure was based on filled prescriptions; low 
adherence may bias the results towards the null. 
Secondly, the study was conducted in Scandinavia, 
and its generalisability to other populations and 
healthcare systems is unknown. Thirdly, although 
high sensitivity and positive predictive values have 
been observed for procedure codes and diagnoses 
recorded in Scandinavian health registers,27 28 data 
on covariates and outcomes in these registers may be 
incomplete or misclassified. With respect to the specific 
codes used for the outcome definition in our study, 
validation studies in the Scandinavian setting have 
not been conducted.27  28 Outcome misclassification 
could have introduced bias in our analyses; however, 
such misclassification is not likely to be different in 
patients receiving SGLT2 inhibitors versus dipeptidyl 
peptidase-4 inhibitors. Finally, although we used an 
active comparator, new user design and estimated 
a propensity score to control for a large number of 
patient characteristics, this was an observational 
study and the risk of unmeasured confounding cannot 
be ruled out.
Conclusions
In this analysis of nationwide registers from three 
countries, use of SGLT2 inhibitors, compared with 
dipeptidyl peptidase-4 inhibitors, was associated with 
a reduced risk of serious renal events. Complementing 
data from clinical trials, this study provides further 
support for the use of SGLT2 inhibitors in a broad 
range of patients with type 2 diabetes.
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